 |
|  |
Feb-20-19 | Resumed |
Citigroup |
Neutral |
$41 |
|
Jan-31-19 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
Jan-31-19 | Upgrade |
Argus |
Hold → Buy |
|
|
Jan-23-19 | Downgrade |
UBS |
Buy → Neutral |
|
|
Dec-11-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
Nov-01-18 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
|
|
Jun-08-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$45 |
|
Apr-05-18 | Downgrade |
Barclays |
Overweight → Equal Weight |
$41 → $38 |
|
Jan-29-18 | Reiterated |
SunTrust |
Hold |
$33 → $40 |
|
Sep-20-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
Jul-20-17 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
May-16-17 | Downgrade |
Citigroup |
Neutral → Sell |
|
|
Dec-02-16 | Initiated |
Guggenheim |
Neutral |
|
|
Nov-02-16 | Downgrade |
Argus |
Buy → Hold |
|
|
Oct-13-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
Jun-20-16 | Reiterated |
Jefferies |
Buy |
$42 → $40 |
|
May-12-16 | Initiated |
Berenberg |
Hold |
$38 |
|
May-04-16 | Reiterated |
UBS |
Buy |
$36 → $38 |
|
Apr-18-16 | Resumed |
Goldman |
Neutral |
$35 |
|
Apr-07-16 | Resumed |
Morgan Stanley |
Equal-Weight |
$35 |
|
|
 |
Feb-23-19 12:04PM | The Dogs of the Dow Start 2019 Slow Motley Fool |
Feb-22-19 06:05PM | Trump nominates Kelly Craft as UN ambassador CNBC |
01:27PM | Intel, Pfizer Lead Dow Jones Rally; 3 Stocks Explode Higher On Earnings Investor's Business Daily |
01:01PM | U.S. closes IV solution shortage antitrust probe, Baxter says Reuters |
10:47AM | Pfizer executive Sally Susman to host 2020 presidential fundraiser for Democrat Kirsten Gillibrand CNBC |
09:04AM | Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks |
07:41AM | Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review Zacks |
12:52AM | Icon PLC (ICLR) Q4 2018 Earnings Conference Call Transcript Motley Fool |
12:49AM | EXACT Sciences Corporation (EXAS) Q4 2018 Earnings Conference Call Transcript Motley Fool |
Feb-21-19 09:39PM | What Pharma Investors Need to Know About Pfizer's Latest Disaster Motley Fool |
08:33AM | Fears of Amazon appear overblown as companies that fretted competition went on to beat market CNBC |
Feb-20-19 04:48PM | Market Recap for Wednesday February 20 Yahoo Finance Video |
04:26PM | Better Buy: Pfizer vs. Eli Lilly Motley Fool |
08:42AM | Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study Zacks |
Feb-19-19 05:17PM | Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript Motley Fool |
10:30AM | Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials Business Wire |
10:07AM | What's in Store for Sangamo (SGMO) This Earnings Season? Zacks |
09:32AM | Pfizer Receives European Approval for ZIRABEV (bevacizumab), a Biosimilar to Avastin®* Business Wire |
08:30AM | Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045 PR Newswire |
07:22AM | Pfizer-Lilly drug shown to help reduce back pain in late-stage trial Reuters |
07:17AM | Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster Motley Fool |
06:56AM | Higher dose of Pfizer-Lilly drug helps reduce back pain in study Reuters |
06:45AM | Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain PR Newswire |
Feb-18-19 08:10AM | Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks |
06:00AM | Big Pharma Cant Resist Big Mergers. Heres Why. Barrons.com |
Feb-16-19 05:10PM | Merck, Pfizer drug combo extends kidney cancer survival -study Reuters |
Feb-15-19 04:18PM | Pharmacia Corporation (Old Monsanto) -- Moody's announces completion of a periodic review of ratings of Pfizer Inc. Moody's |
01:21PM | This Is One Company That Could Break Up Bristol-Celgene Deal Investor's Business Daily |
08:56AM | Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks |
Feb-14-19 04:45PM | Bayer stresses drug's tolerability in bid for prostate cancer market Reuters |
07:50AM | The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga |
05:00AM | Pfizer still holds the lead in the erectile dysfunction market even as Viagra sales falter CNBC |
Feb-13-19 03:36PM | Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks |
01:25PM | Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 Zacks |
05:00AM | Dogs of the Dow and a 3 Top Dogs Strategy MoneyShow |
Feb-12-19 05:57PM | Bristol-Myers' Sprycel Gets European Nod for Label Expansion Zacks |
10:10AM | Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Zacks |
09:38AM | Stock Market News For Feb 12, 2019 Zacks |
07:17AM | Better Buy: Gilead Sciences vs. Pfizer Motley Fool |
Feb-11-19 08:01PM | Merck, Pfizer combo treatment boosts kidney cancer survival Reuters |
05:44PM | FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma PR Newswire |
05:00PM | Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer PR Newswire |
04:07PM | Stocks Start Week of Trade Talks on Muted Note: Markets Wrap Bloomberg |
12:07PM | Stocks making the biggest moves midday: Avis Budget Group, Pfizer, Tesla & more CNBC |
09:31AM | Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake Zacks |
Feb-10-19 05:37PM | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga |
Feb-08-19 04:14PM | This Gene Therapy Stock Could Soon Hit The Auction Block Here's Why Investor's Business Daily |
09:53AM | Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters |
09:41AM | Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters |
07:51AM | Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs Zacks |
07:29AM | Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod Zacks |
07:20AM | Pfizer Japan recalls high blood pressure drug Amvalo due to carcinogen Reuters |
05:00AM | Buying the Dow Stocks With the Highest Dividends Is a Winning Strategy Barrons.com |
Feb-07-19 09:00AM | Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19 Zacks |
Feb-06-19 05:52PM | At least four pharma CEOs to testify at Senate drug pricing hearing Reuters |
01:48PM | Eli Lilly Stock Falls Because 2019 Isnt 2018 Barrons.com |
01:37PM | At least four pharma CEOs to testify at Senate drug pricing hearing Reuters |
12:16PM | Congress invites 7 drugmakers to testify at potentially hostile hearing on drug prices. Here's what they're saying CNBC |
09:44AM | Pfizer CEO Bourla plans to testify at Senate drug pricing hearing Reuters |
07:48AM | Cancer-Vaccine Maker BioNTech Considering an IPO in U.S. Bloomberg |
06:08AM | Winners & Losers from Trump's State of the Union Address Zacks |
Feb-05-19 04:06PM | Merck CEO Frazier to testify at Senate drug pricing hearing Reuters |
11:38AM | Pharma execs will testify before Congress 'one way or another,' US senator says CNBC |
08:07AM | Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies Zacks |
08:03AM | Corporate Profits' New Enemy Is the 'Dollar Vortex' Investopedia |
Feb-04-19 09:47PM | Here's Why Exact Sciences Soared 42.8% in January Motley Fool |
08:48AM | Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod Zacks |
08:05AM | The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer Zacks |
Feb-03-19 09:16AM | Pfizer's Next 3 Years: What Investors Can Expect Motley Fool |
09:01AM | A War on High Drug Prices Could Boost Biosimilars Motley Fool |
Feb-02-19 02:17PM | Pricing Pressure a Hard Pill for Pharma to Swallow Barrons.com |
Feb-01-19 08:01PM | It's Official: Trump Proposes Plan to Stop Skyrocketing Drug Prices Motley Fool |
02:24PM | Top Analyst Reports for Boeing, Thermo Fisher & Anthem Zacks |
10:15AM | Pharma Catches Another Case Of M&A Fever Benzinga |
09:17AM | Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations Business Wire |
08:27AM | Dow 30 Stock Roundup: MCD, BA, 3M, MSFT, PFE, V Earnings Impress Zacks |
08:15AM | Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY Zacks |
Jan-31-19 12:06PM | Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status Zacks |
11:27AM | Pfizer Stocks Dark Period Might Finally Be Over Barrons.com |
09:50AM | Pfizer Rises 3% Investing.com |
Jan-30-19 11:45PM | Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals |
07:01PM | Jim Cramer: When Is a Miss Not a Miss? TheStreet.com |
04:34PM | Edited Transcript of PFE earnings conference call or presentation 29-Jan-19 3:00pm GMT Thomson Reuters StreetEvents |
02:47PM | What Should Apple Do With Its Cash? InvestorPlace |
12:46PM | Pfizer's Near-Term Correction Could Be Over TheStreet.com |
11:03AM | Pfizer Beats Expectations but Reaction Is Muted GuruFocus.com |
09:30AM | Company News For Jan 30, 2019 Zacks |
08:52AM | Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study Zacks |
08:46AM | Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid Zacks |
08:16AM | 3 Big Pharmas Expecting a Softer 2019 Motley Fool |
07:28AM | A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype Motley Fool |
07:00AM | New Jerseys College Savings Plan Bought Up AT&T, Amazon, and GM Stock Barrons.com |
12:40AM | Pfizer Well-Positioned, Undervalued Morningstar |
Jan-29-19 10:14PM | Pfizer (PFE) Q4 2018 Earnings Conference Call Transcript Motley Fool |
09:34PM | Better Buy: Johnson & Johnson vs. Pfizer Motley Fool |
08:17PM | [$$] Pfizer Results Hurt by Pricing Challenges The Wall Street Journal |
06:41PM | Here's when an earnings miss isn't really a miss: Jim Cramer CNBC |
05:20PM | US Market Indexes Close Flat on Tuesday GuruFocus.com |
05:12PM | What Happened in the Stock Market Today Motley Fool |
04:57PM | 3 Stocks Move Tuesday GuruFocus.com |
|
|
|
 |
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LANKLER DOUGLAS M | Executive Vice President | Feb 01 | Sale | 42.75 | 5,000 | 213,750 | 40,057 | Feb 01 07:21 PM | Dolsten Mikael | President R&D | Jan 31 | Option Exercise | 29.78 | 125,968 | 3,751,425 | 362,051 | Feb 01 07:28 PM | LANKLER DOUGLAS M | Executive Vice President | Jan 30 | Sale | 41.19 | 38,800 | 1,598,071 | 45,057 | Feb 01 07:21 PM | READ IAN C | Chairman & CEO | Nov 02 | Option Exercise | 26.64 | 1,100,201 | 29,312,588 | 1,760,958 | Nov 06 03:46 PM | PFIZER INC | 10% Owner | Oct 15 | Buy | 18.00 | 55,556 | 1,000,008 | 22,032,040 | Oct 17 05:17 PM | Dolsten Mikael | President R&D | Sep 13 | Option Exercise | 24.56 | 181,712 | 4,462,167 | 234,299 | Sep 17 04:08 PM | OLSON LAURIE J | Executive Vice President | Aug 13 | Sale | 41.00 | 10,214 | 418,774 | 72,672 | Aug 14 05:04 PM | MACKENZIE ALEXANDER R | Executive Vice President | Aug 03 | Sale | 39.51 | 25,642 | 1,013,171 | 102,412 | Aug 06 03:19 PM | GOETTLER MICHAEL | Group President | Aug 01 | Sale | 39.70 | 19,198 | 762,116 | 11,924 | Aug 03 03:38 PM | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Aug 01 | Sale | 40.16 | 26,814 | 1,076,933 | 83,846 | Aug 03 03:36 PM | LUND-JURGENSEN KIRSTEN | Executive Vice President | Aug 01 | Sale | 40.04 | 20,942 | 838,572 | 4,643 | Aug 03 03:35 PM | DAMELIO FRANK A | Executive Vice President | Aug 01 | Sale | 40.00 | 150,484 | 6,019,360 | 337,391 | Aug 03 03:33 PM | SUSMAN SALLY | Executive Vice President | Jul 20 | Sale | 37.22 | 40,381 | 1,502,925 | 115,096 | Jul 24 01:09 PM | READ IAN C | Chairman & CEO | Jul 16 | Sale | 37.36 | 486,753 | 18,186,315 | 659,440 | Jul 17 04:59 PM | OLSON LAURIE J | Executive Vice President | Jun 06 | Sale | 36.45 | 19,000 | 692,582 | 82,886 | Jun 08 01:11 PM | CORNWELL W DON | Director | Jun 04 | Sale | 36.40 | 5,223 | 190,117 | 0 | Jun 05 04:44 PM | READ IAN C | Chairman & CEO | May 01 | Sale | 36.01 | 132,312 | 4,764,081 | 1,144,703 | May 03 04:19 PM | JOHNSON RADY A | Executive Vice President | Mar 13 | Sale | 36.55 | 27,323 | 998,666 | 43,178 | Mar 14 05:19 PM | LANKLER DOUGLAS M | Executive Vice President | Mar 13 | Sale | 36.89 | 50,000 | 1,844,398 | 83,857 | Mar 14 05:13 PM | Dolsten Mikael | President R&D | Mar 09 | Sale | 36.59 | 69,699 | 2,550,394 | 51,185 | Mar 12 05:01 PM | HILL CHARLES H | Executive Vice President | Mar 06 | Sale | 35.76 | 42,393 | 1,515,985 | 57,328 | Mar 07 04:09 PM | Dolsten Mikael | President R&D | Mar 02 | Sale | 35.85 | 13,986 | 501,398 | 120,884 | Mar 05 09:23 AM | HILL CHARLES H | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 101,872 | 2,788,237 | 207,942 | Mar 02 03:24 PM | YOUNG JOHN D | Group President | Feb 28 | Option Exercise | 27.37 | 121,145 | 3,315,739 | 362,707 | Mar 02 04:10 PM | OLSON LAURIE J | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 38,546 | 1,055,004 | 132,702 | Mar 02 04:02 PM | READ IAN C | Chairman & CEO | Feb 28 | Option Exercise | 27.37 | 649,780 | 17,784,479 | 1,774,184 | Mar 02 04:03 PM | SUSMAN SALLY | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 110,132 | 3,014,313 | 245,362 | Mar 02 04:03 PM | LUND-JURGENSEN KIRSTEN | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 19,273 | 527,502 | 39,801 | Mar 02 03:44 PM | JOHNSON RADY A | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 19,273 | 527,502 | 85,910 | Mar 02 03:44 PM | LANKLER DOUGLAS M | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 46,806 | 1,281,080 | 171,276 | Mar 02 03:44 PM | Lewis-Hall Freda C | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 104,626 | 2,863,614 | 384,219 | Mar 02 03:44 PM | DAMELIO FRANK A | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 209,251 | 5,727,200 | 655,161 | Mar 02 03:24 PM | BOURLA ALBERT | Chief Operating Officer | Feb 28 | Option Exercise | 27.37 | 39,923 | 1,092,693 | 184,120 | Mar 02 03:24 PM | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 28 | Option Exercise | 27.37 | 33,040 | 904,305 | 136,847 | Mar 02 03:24 PM | Dolsten Mikael | President R&D | Feb 28 | Option Exercise | 27.37 | 198,238 | 5,425,774 | 293,352 | Mar 02 03:24 PM | HILL CHARLES H | Executive Vice President | Feb 28 | Sale | 36.83 | 26,779 | 986,292 | 181,163 | Mar 02 03:24 PM | SUSMAN SALLY | Executive Vice President | Feb 27 | Sale | 37.03 | 33,368 | 1,235,591 | 135,230 | Feb 28 06:14 PM | Dolsten Mikael | President R&D | Feb 27 | Sale | 37.04 | 64,587 | 2,392,313 | 95,114 | Feb 28 06:04 PM | CORNWELL W DON | Director | Feb 27 | Sale | 37.05 | 300 | 11,115 | 0 | Feb 28 01:29 PM | LUND-JURGENSEN KIRSTEN | Executive Vice President | Feb 26 | Sale | 37.19 | 9,510 | 353,677 | 17,770 | Feb 27 07:38 PM | CORNWELL W DON | Director | Feb 26 | Sale | 36.74 | 1,458 | 53,564 | 0 | Feb 28 01:29 PM | YOUNG JOHN D | Group President | Feb 24 | Option Exercise | 18.90 | 43,520 | 822,528 | 223,733 | Feb 27 08:59 PM | READ IAN C | Chairman & CEO | Feb 24 | Option Exercise | 19.83 | 903,559 | 17,917,265 | 1,560,007 | Feb 27 08:58 PM | OLSON LAURIE J | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 15,716 | 297,032 | 90,222 | Feb 27 07:53 PM | SUSMAN SALLY | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 91,876 | 1,736,456 | 206,972 | Feb 27 07:51 PM | JOHNSON RADY A | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 15,885 | 300,227 | 62,848 | Feb 27 07:43 PM | LANKLER DOUGLAS M | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 28,288 | 534,643 | 112,081 | Feb 27 07:43 PM | Lewis-Hall Freda C | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 91,876 | 1,736,456 | 313,499 | Feb 27 07:43 PM | LUND-JURGENSEN KIRSTEN | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 15,957 | 301,587 | 36,959 | Feb 27 07:38 PM | MACKENZIE ALEXANDER R | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 39,555 | 747,590 | 143,152 | Feb 27 07:38 PM | HILL CHARLES H | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 65,280 | 1,233,792 | 122,609 | Feb 27 07:38 PM | Dolsten Mikael | President R&D | Feb 24 | Option Exercise | 18.90 | 174,081 | 3,290,131 | 225,265 | Feb 27 07:32 PM | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 24 | Option Exercise | 18.90 | 28,288 | 534,643 | 116,769 | Feb 27 07:30 PM | BOURLA ALBERT | Chief Operating Officer | Feb 24 | Option Exercise | 18.90 | 25,387 | 479,814 | 158,170 | Feb 27 07:30 PM | DAMELIO FRANK A | Executive Vice President | Feb 24 | Option Exercise | 18.90 | 174,081 | 3,290,131 | 511,470 | Feb 27 07:30 PM |
|
 |
|
 |
|